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Abstract
Introduction
To improve our understanding of sex differences in the clinical characteristics of Parkin-
son’s Disease, we sought to examine differences in the clinical features and disease sever-
ity of men and women with early treated Parkinson’s Disease (PD) enrolled in a large-scale
clinical trial.
Methods
Analysis was performed of baseline data from the National Institutes of Health Exploratory
Trials in Parkinson’s Disease (NET-PD) Long-term Study-1, a randomized, multi-center,
double-blind, placebo-controlled study of 10 grams of oral creatine/day in individuals with
early, treated PD. We compared mean age at symptom onset, age at PD diagnosis, and
age at randomization between men and women using t-test statistics. Sex differences in
clinical features were evaluated, including: symptoms at diagnosis (motor) and symptoms
at randomization (motor, non-motor, and daily functioning).
Results
1,741 participants were enrolled (62.5% male). No differences were detected in mean age
at PD onset, age at PD diagnosis, age at randomization, motor symptoms, or daily
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functioning between men and women. Differences in non-motor symptoms were observed,
with women demonstrating better performance compared to men on SCOPA-COG (Z =
5.064, p<0.0001) and Symbol Digit Modality measures (Z = 5.221, p<0.0001).
Conclusions
Overall, men and women did not demonstrate differences in clinical motor features early in
the course of PD. However, the differences observed in non-motor cognitive symptoms sug-
gests further assessment of the influence of sex on non-motor symptoms in later stages of
PD is warranted.
Introduction
Sex-specific differences are often manifesting in disease risk, clinical manifestations, clinical
management, and prognosis in widely varied disorders ranging from cardiovascular disease to
neurodegenerative disorders.[1–6] Underlying factors associated with these disparities include:
differences in disease biology, differing pharmacokinetics and pharmacodynamics, as well as
variations in provider treatment practice. Recommendations for more systematic evaluation of
sex differences in health in both pre-clinical and clinical research, and greater participation in
clinical trials by women, have been endorsed by several professional organizations and govern-
ment agencies.[7–9]
Although Parkinson’s Disease (PD) is a common disorder with aging[10], sex differences
are not well understood. The incidence and prevalence of disease are greater in men, who carry
an approximate 1.5–2 times greater risk for development of PD compared to women.[11–15]
While there is consensus regarding disparate risk of developing PD, there are conflicting data
regarding sex differences in the timing of symptom onset and the nature of clinical manifesta-
tions. Sex differences in clinical manifestations may indicate important mechanistic factors
with respect to neurobiology, therapeutic development, disease prevention and clinical man-
agement.[16–18] In this analysis of participants in a large scale clinical trial, we sought to
improve current knowledge of sex differences in the clinical phenotype of early, treated PD.
Methods
We analyzed baseline data from the National Institutes of Health Exploratory Trials in Parkin-
son’s Disease (NET-PD) Long-term Study-1 (LS-1), a randomized, multi-center, double-blind,
placebo-controlled study of 10 grams of oral creatine/day in individuals who were within 5
years of PD diagnosis and who were on dopaminergic therapy for fewer than two years (early
treated PD). Between March 2007 and May 2010, 1,741 subjects from 45 United States and
Canadian sites were enrolled. Details of the trial design, baseline sample characteristics, and
the primary trial results have been published.[19, 20]
We sought to evaluate whether there are sex differences in age milestones related to disease
presentation and trial randomization, including: age at symptom onset, age at PD diagnosis,
age at randomization, years since symptom onset, years since PD diagnosis, and length of time
between symptom onset and diagnosis. We also evaluated differences in specific clinical fea-
tures: retrospective patient-reported symptoms at the time of diagnosis (motor symptoms) and
symptoms present at the time of randomization (motor symptoms, non-motor symptoms, and
daily functioning).
Sex Differences in Clinical Features of Parkinson's Disease
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Statistical methods
Normality of the data was tested using the Kolmogorov Smirnov test. Differences in propor-
tions for categorical variables (demographic characteristics) between men and women were
evaluated using the chi-square test or the Fisher exact test depending on assumptions. Age
at symptom onset, age at PD diagnosis, age at randomization, years since symptom onset,
years since PD diagnosis, and length of time between symptom onset and diagnosis were ana-
lyzed for differences in demographic characteristics between men and women; adjustment for
multiple comparisons was made via Bonferroni correction with a type I error level of 0.05/
6 = 0.0083. Disease presentation and randomization age milestones were analyzed using a
series of t-tests for unequal variances. We compared men and women on their time from
symptom onset to PD diagnosis using the Wilcoxon rank sum test because this variable was
not normally distributed.
We evaluated three outcomes related to clinical features: 1. Motor symptoms at the time of
diagnosis and at the time of trial randomization, 2. non-motor symptoms at the time of trial
randomization, and 3. daily functioning at the time of trial randomization. Motor symptoms
at diagnosis were defined by: resting tremor, rigidity, bradykinesia, postural instability, and
other symptoms. To evaluate differences between men and women in motor symptoms at
randomization, we compared five variables (ambulatory capacity, UPDRS motor score, the
percent of the waking day that dyskinesias are present, the presence of early morning dystonia,
and the percent of the waking day that the subject is "Off" on average) between men and
women. Ambulatory capacity identifies the sum of the response to the following questions
administered in the UPDRS: (i) falling, (ii) freezing, (iii) walking, (iv) gait and (v) postural sta-
bility. From the UPDRS part IV (Complications of therapy), we assessed the proportion of the
waking day that dyskinesias were present with three categories of response: none, 1–25% of the
day and>25% of the day. Due to small sample size in some categories, we collapsed the catego-
ries of 1–25% and>25% of the day into present (some part of the day) versus absent (none).
We assessed the proportion of the waking day that the subject is "Off" on average with five
categories of response: none, 1–25% of the day, 26–50% of the day, 51–75% of the day and 76–
100% of the day. Again, due to small sample size in some categories, we collapsed the categories
of 26–50%, 51–75% and 76–100% into one category of>25% of the day.
We compared non-motor symptoms at the time of trial randomization between men and
women using six non-motor variables: UPDRS Part I (Mentation) score, Scale for Outcome of
Parkinson Disease Cognition (SCOPA-COG), Symbol Digit Modalities (SDM), Beck Depres-
sion Inventory II total score (BDI), self-reported symptomatic orthostasis, and self-reported
sleep disturbance.
We compared daily functioning at the time of randomization between men and women
using seven global functioning variables: UPDRS Part II (ADL) score, Schwab and England
ADL (S&E ADL), total functional capacity (TFC), Parkinson’s Disease Questionnaire (PDQ-
39) summary index, EuroQoL 5-D (EQ5D) utility score, Modified Rankin Scale, and care level.
Twenty three variables related to clinical features were tested for differences between men
and women; therefore adjustment for multiple comparisons was made via Bonferroni correc-
tion with a type I error level of 0.05/23 = 0.002.
We also evaluated differences between men and women in motor and non-motor symptoms
at randomization and daily functioning at the time of randomization after adjustment for age,
marital status, duration of PD, and levodopa equivalent daily dose at randomization using: (i)
linear regression (for ambulatory capacity, UPDRS Part I–Mentation, UPDRS Part II–ADL,
UPDRS Part III—Motor, SCOPA-COG, SDM, BDI, S&E ADL, TFC, PDQ-39 Summary Index
and EQ5D; (ii) logistic regression (for percent of the waking day that dyskinesias were present,
Sex Differences in Clinical Features of Parkinson's Disease
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presence of early morning dystonia, self-reported symptomatic orthostasis, self-reported sleep
disturbance, and care level); and (iii) multinomial logistic regression (for the percent of the
waking day that the subject was "Off" on average, using none as the reference category and for
Modified Rankin Scale using “No significant disability despite symptoms” as the reference
category).
Ethics Statement
The NET-PD LS-1 trial was registered at www.clinicaltrials.gov (NCT00449865). Study proce-
dures were reviewed and approved by the institutional review board for each site, prior to
enrollment of participants, who each provided written informed consent to study participation.
Participating sites are listed in the Appendix.
Results
Of the 1,741 total participants, 1,123 were male (62.5%). Men were more likely than women to
be married at randomization (Chi-square statistic = 67.8, p<0.0001). Other demographic char-
acteristics were not different between men and women (Table 1). We did not observe differ-
ences between men and women in mean age at PD symptom onset (t = -1.27, df = 1186.3,
p = 0.20), age at PD diagnosis (t = -1.37, df = 1191.7, p = 0.17), or age at randomization (t =
-1.38, df = 1194.3, p = 0.16). The length of time between PD symptom onset and PD diagnosis
was a mean 1.7 years for both men (SD 1.7) and women (SD 2.0) (Wilcoxon Rank sum test =
-0.44, df = 1472.2, p-value = 0.66). Men and women were enrolled into the study on average
3.2 years (SD 2.0) and 3.3 years (SD 2.3) after symptom onset, respectively (t-test for unequal
variance = -0.29, df = 1453, p-value = 0.77). Randomization occurred a mean of 1.5 years (SD
1.1) after PD diagnosis for both sexes (t-test = 0.2, df = 1739, p-value = 0.84).
There were no differences in the proportion of men and women demonstrating any cardinal
features of PD (resting tremor, rigidity, bradykinesia, postural instability, or “other symp-
toms”) at the time of diagnosis (Table 2). The three most common “other symptoms” reported
as being present at the time of diagnosis included: gait disturbance (n = 68), micrographia or
handwriting change (n = 38), and hypophonia or voice change (n = 29). Additional symptoms
reported less frequently included: drooling or swallowing dysfunction, hypomimia, dystonia,
fine motor incoordination, non-rest tremor, anosmia, sensory disturbance, weakness, stooped
posture, muscle cramping, problems with memory, pain, mood change, fatigue, constipation,
sleep disturbance, freezing, and falls. There were no differences between men and women in
motor symptom frequency or severity at the time of randomization (Table 2), including after
controlling for age, marital status, duration and amount of levodopa equivalence daily dose at
randomization.
In terms of non-motor features, women demonstrated better SCOPA-COG and better SDM
performance compared to men (Table 3). Initial analysis of daily functioning revealed better
UPDRS ADL performance for women compared to men (Table 4). After controlling for age,
marital status, duration and amount of levodopa equivalence daily dose at randomization, dif-
ferences in SCOPA-COG total score (p<0.0001) and SDM (p<0.0001) remained significant.
However, this did not hold true for differences in UPDRS ADL (p = 0.003).
Discussion
PD is expected to affect more than 9 million individuals worldwide by 2030.[21, 22] This
progressive neurodegenerative disorder significantly impacts quality of life and results in high
societal economic burden.[22] Understanding sex-specific features of presentation, symptom-
atology, response to treatment, functional impact, and disease burden represents one critical
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aspect to improving care delivery to a growing population. Improved knowledge of sex-related
differences will be valuable for clinical trial planning and assessment of treatment response.
Underlying the concept of sex-related differences, it has been hypothesized that endogenous
and exogenous estrogen exposure may be one of the factors involved in neuroprotection or
individual symptomatic effects in Parkinson’s disease.[23, 24] The MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) mouse model of PD demonstrates a sex-based differential in
nigrostriatal degeneration, with greater MPTP-induced toxicity observed in males. In addition,
administration of 17β estradiol is protective against MPTP-induced toxicity in both sexes
(mice). This positive effect is potentially mediated by estrogen receptors, expressed on both
glial and neuronal cells.[25]
However, clinical studies of sex and PD are less clear regarding sex-related differences,
reporting varied and sometimes conflicting results. For instance, some studies estimate age at
symptom onset to be approximately two years later in women compared to men [11, 26],
Table 1. Demographic Characteristics (N = 1,741).
Female Male
n % n %
Age (years)
<30 1 0.2 0 0
30–40 9 1.5 13 1.2
40–50 73 11.8 98 8.7
50–60 174 28.2 307 27.3
60–70 228 36.9 456 40.6
70–80 118 19.1 225 20.0
80 15 2.4 24 2.1
Non-Hispanic whites 559 90.5 1012 90.1
Education
<High school 33 5.3 50 4.5
High school/GED 96 15.5 127 11.3
Some college/associate 181 29.3 236 21.0
Bachelors 163 26.4 314 28.0
Graduate/professional 145 23.5 396 35.3
Marital Status
Never Married 37 6.0 55 4.9
Now Married 433 70.1 959 85.4
Widowed/Divorced/Separated 148 23.9 109 9.7
Care level
Chronic care/Full-time skilled nursing 7 1.1 12 1.1
Home 611 98.9 1111 98.9
Current employment activities
1.Working Full Time 174 28.2 495 44.1
2.Retired 231 37.4 427 38.0
3.Working part-time 98 15.9 134 11.9
4.Not working, on disability pay 31 5.0 41 3.7
5.Homemaker 61 9.9 0 0.0
6.Unemployed and looking for work 9 1.5 15 1.3
7.Other 11 1.8 11 1.0
8.Student 2 0.3 0 0.0
doi:10.1371/journal.pone.0133002.t001
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however, this has not been replicated in other studies [27–30]. Similarly, a delay in the timing
of initial evaluation by a PD specialist for women compared to men has also been reported but
not replicated.[31] In early PD, before treatment with levodopa or dopamine agonists, some
studies show no difference in manifestation or severity of motor symptoms between men and
women.[11, 26, 27] On the other hand, two studies suggest that women more often present
with tremor-predominant PD.[26, 32], while other studies show higher UPDRS postural stabil-
ity scores in females [27, 32], and greater rigidity in males [27]. There may be sex differences in
Table 2. Motor symptoms ‡.
Female Male p-value Sig
At the time of diagnosis of Parkinson Disease n % n %
Resting Tremor † 0.024 No
Yes 511 82.8 877 78.2
No 106 17.2 244 21.8
Rigidity † 0.651 No
Yes 522 86.6 962 87.4
No 81 13.4 139 12.6
Bradykinesia † 0.854 No
Yes 566 92.2 1021 91.8
No 48 7.8 91 8.2
Postural instability † 0.201 No
Yes 127 20.8 202 18.3
No 483 79.2 903 81.7
Other motor symptoms † 0.595 No
Yes 110 17.9 188 16.9
No 503 82.1 925 83.1
At the time of trial randomization
n Mean(SD) n Mean(SD)
Ambulatory Capacity score** 616 1.8 (1.6) 1123 1.6 (1.5) ¥ 0.014 No
UPDRS motor 615 17.0 (8.6) 1118 18.2 (8.2) * 0.003 No
n % n %
Individuals with dyskinesias † 0.021 No
Some part of the day 31 5.0 31 2.8
None of the day 587 95.0 1091 97.2
Individuals with early morning dystonia † 0.003 No
Yes 106 17.2 133 11.9
No 512 82.9 989 88.2
Individuals with "Off" periods + 0.819 No
More than 25% of the day 18 2.9 39 3.48
1–25% of the day 119 19.3 215 19.16
No “Off” periods 481 77.8 868 77.36
Sig: Significant after Bonferroni correction on the type I error level = 0.05/23 = 0.002.
† Two-sided Fisher exact test.
+ Chi square statistic = 0.399 (degrees of freedom = 2).
¥ t-test for unequal variances = 2.47 (Degrees of freedom = 1174.3).
* t-test for equal variances = -2.97 (Degrees of freedom = 1731).
‡ Differences between number of observed values and 1741 subjects is due to missing values for these variables.
** Sum of the response to the following UPDRS questions: (i) falling, (ii) freezing, (iii) walking, (iv) gait and (v) postural stability.
doi:10.1371/journal.pone.0133002.t002
Sex Differences in Clinical Features of Parkinson's Disease
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Table 3. Non-motor symptoms at the time of trial randomization‡.
Female Male Test
Statistic
p-value Sig
n Mean (SD) n Mean (SD)
UPDRS Mentation score 618 1.3 (1.4) 1123 1.3 (1.4) † -0.567 0.571 No
SCOPA-COG total score 615 31.1 (5.5) 1116 29.8 (5.2) † 5.064 <0.0001 Yes
Symbol Digit Modalities (total correct responses) 617 46.4 (12.0) 1119 43.3 (11.4) † 5.221 <0.0001 Yes
Beck Depression Inventory total score 615 7.1 (5.7) 1121 6.8 (5.5) † 0.941 0.347 No
n % n %
Individuals with sleep disturbance (e.g. insomnia or hypersomnolence) + 0.795 No
Yes 228 36.9 407 36.3
No 390 63.1 715 63.7
Individuals with symptomatic orthostasis + 0.662 No
Yes 81 13.1 156 13.9
No 537 86.9 966 86.1
† Wilcoxon two sample test statistic two sided normal approximation.
+ Two-sided Fisher exact test.
‡ Differences between observed values and 1741 subjects is due to missing values for these variables.
Sig: Significant adjusting for Bonferroni correction on the type I error level = 0.05/23 = 0.002.
doi:10.1371/journal.pone.0133002.t003
Table 4. Daily functioning features at the time of trial randomization‡.
Female Male Test Statistic p-value Sig
n Mean (SD) n Mean (SD)
UPDRS ADL score 617 6.8 (4.1) 1123 7.4 (3.9) † -3.523 0.0004 Yes £
S&E ADL score 618 91.0 (6.9) 1122 91.1 (6.8) † -0.012 0.990 No
TFC 617 11.9 (1.6) 1122 12.1 (1.3) † -0.822 0.411 No
PDQ-39 Summary Index score 617 14.0 (10.9) 1121 12.8 (10.5) † 2.268 0.023 No
EuroQol (generic instrument) EQ5D utility score 618 0.8 (0.2) 1123 0.8 (0.2) † -1.992 0.046 No
n % n %
Modified Rankin Scale score + 0.026 No
1. No Symptoms at all 14 2.3 9 0.8
2. No significant disability despite symptoms 459 74.3 885 78.8
3. Slight disability 134 21.7 211 18.8
4. Moderate Disability 11 1.8 18 1.6
Care level ¥ 1.000 No
Chronic care/Full-time skilled nursing 7 1.1 12 1.1
Home 611 98.9 1111 98.9
† Wilcoxon two sample test statistic two sided normal approximation.
+ Chi square statistic = 9.289 (degrees of freedom = 3).
¥ Two-sided Fisher exact test.
‡ Differences between observed values and 1741 subjects is due to missing values for these variables.
Sig: Significant adjusting for Bonferroni correction on the type I error level = 0.05/23 = 0.002.
£: Not significant after controlling for age, marital status, duration and amount of levodopa equivalent daily dose at randomization: p = 0.003.
doi:10.1371/journal.pone.0133002.t004
Sex Differences in Clinical Features of Parkinson's Disease
PLOS ONE | DOI:10.1371/journal.pone.0133002 July 14, 2015 7 / 11
non-motor symptoms as well: women report higher severity of cardiovascular, fatigue, and
mood-related symptoms [19, 25] compared to men who report higher severity of sexual dys-
function [14], sialorrhea [14, 23, 24] and daytime sleepiness [14, 33]. At least three studies
reporting on depression in PD indicate greater occurrence [27, 32, 34] and severity in women,
while yet another study found no sex-related difference.[35] When examining dementia in PD,
one study showed no sex differences in the prevalence of dementia,[36] while another study
found greater development of dementia in men compared to women over a 10-year period
[37]. Women have also been found to have higher Hoehn and Yahr stage [27, 38] and greater
impairment in activities of daily living (ADLs) [27] at presentation. These conflicting results
regarding potential sex differences in the epidemiology and clinical expression of PD require
further clarification.
Our study of over 1700 individuals with early, treated PD did not find differences between
men and women in age-based disease milestones or motor features. We previously reported a
small, clinically-insignificant difference in motor symptoms between men and women in this
cohort, however, this difference was not present following Bonferroni correction for multiple
comparisons in the current analysis.[39]
There were, however, small-magnitude differences in non-motor symptoms. Women dem-
onstrated better cognitive performance on two measures: the Symbol Digit Modalities Test
(SDMT), a screening assessment for cognitive impairment, and the SCOPA-COG, a measure
of memory and learning, attention, executive function, and visuo-spatial function. The absolute
magnitude of difference in cognition scores between men and women was 1.3 for SCOPA-
COG and 3.1 for SDMT, which may fall below the threshold of clinical significance. It is
unclear whether the difference in cognitive performance represents evidence of a sex-specific
effect of PD or represents general sex differences in the performance of cognitive tests. There
are conflicting reports in the literature regarding the persistence of sex-specific differences in
cognition with aging.[40, 41] The small difference in UPDRS ADL subscale outcomes was not
found to be significant after controlling for age, marital status, and levodopa equivalent daily
dose. Further, the small magnitude 0.6 point difference is less than what is typically considered
a clinically meaningful difference.[42]
The varied results from previously published studies may relate to methodological differ-
ences in study design, such as prospective or retrospective data acquisition and differences in
the study population. Sex differences may also vary throughout the course of PD. Of previously
published studies, those with small samples were more likely to report sex differences in vari-
ous clinical features; many of these findings equalized in larger samples. In our study of the
largest clinical trial of PD patients to date, there were sex differences in non-motor manifesta-
tions, but we did not detect differences in disease onset, diagnosis, or motor symptoms. In our
previous analysis, we showed that there was no difference in treatment between men and
women in type of medications used or levodopa equivalent dosing.[39]
Our secondary analysis is strengthened by the large sample size and prospective acquisition
of a broad battery of clinician-administered and self-report assessments, which allowed us to
examine many domains of PD. The selected cognitive battery was intended to focus on cogni-
tive deficits in PD, using a general screen (SDMT), as well as disease-specific assessments
(UPDRS Part I Mentation and SCOPA-COG). However, this sample was drawn from a clinical
trial designed to test the effects of a drug, not directly for epidemiological research. As a result,
it is possible that our cohort of trial volunteers may not fully represent the general population
of patients with PD.
The difference in cognition scores between men and women may represent an important
finding. Increasing cognitive impairment correlates with overall disability, and PD with
dementia is associated with lower quality of life and a higher degree of caregiver burden
Sex Differences in Clinical Features of Parkinson's Disease
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compared to PD without dementia.[43] Thus, this difference warrants further evaluation, espe-
cially if magnified later in the course of PD, at a time when greater disease burden would be
anticipated. Further research is needed to elucidate potential differences in the long-term
course of clinical signs and symptoms of PD in men and women, and to better delineate the
significance of early sex-differences in non-motor symptoms.
Appendix
Participating sites in the LS-1 study included: University of Alabama-Birmingham, University
of South Florida, University of Southern California, Emory University School of Medicine,
Oregon Health & Science University, University of Colorado, Johns Hopkins University, Uni-
versity of Texas Southwestern Medical Center, University of California San Francisco, Univer-
sity of Florida, Duke University, Louisiana State University Health Science Center-Shreveport,
Michigan State University, Rush University Medical Center, University of Calgary, University
of Pennsylvania, Beth Israel Deaconess Medical Center, Southern Illinois University, Univer-
sity of Michigan, Brigham and Women’s Hospital, University of Miami, Medical University of
South Carolina, Pacific Health Research and Education Institute, University of Alberta, Wash-
ington University, University of Maryland School of Medicine, University of Vermont, North-
western University, University of Kansas Medical Center, University of Kentucky, Dartmouth
Hitchcock Medical Center, SUNY Downstate Medical Center, Thomas Jefferson University,
Baylor College of Medicine, Georgia Health Sciences University, Institute for Neurodegenera-
tive Disorders-New Haven, The Parkinson’s & Movement Disorder Institute-Fountain Valley,
University of Virginia, Vanderbilt University Medical Center, Barrow Neurological Institute,
UMDNJ Robert Wood Johnson Medical School, Malcolm Randall VAMedical Center, Univer-
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